Counselors in Rose Hill, NC Accepting Medicare

8 Counselors found. Showing 1 - 8

Miss Teondra Bannerman Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 318 S Sycamore St, Rose Hill, NC 28458 Phone: 910-447-2509

Ms. Christine Schneider, M.A., LMFTI, LMFT-A Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 416 W. Ridge St., Rose Hill, NC 28458 Phone: 910-289-2610

Ms. Shanata N Edwards, LCAS-A Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 416 West Ridge Street, Rose Hill, NC 28458 Phone: 910-289-2610

Kristie White, LCAS-A Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 416 W Ridge Street, Rose Hill, NC 28458 Phone: 910-289-2610

Simonne Murray, NCSC Counselor - School Medicare: Not Enrolled in Medicare Practice Location: 1014 Pasture Branch Rd, Rose Hill, NC 28458 Phone: 910-284-8494

Shelley Marie Moorefield, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 416 W Ridge St, Rose Hill, NC 28458 Phone: 910-289-2610    Fax: 910-289-4410

Ms. Tai A Kulenic, MPS, LPC, ATR-BC Counselor Medicare: Not Enrolled in Medicare Practice Location: 416 W. Ridge Street, Rose Hill, NC 28458 Phone: 910-289-2610    Fax: 910-289-4410

Ms. Pamela Bannerman-smith Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 319 N Sycamore St, Rose Hill, NC 28458 Phone: 910-284-1486

News Archive

Conmed second quarter net revenue increases 13.0% to $16.7 million

Conmed Healthcare Management, Inc. today announced financial results for the three- and six-month periods ended June 30, 2011.

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007.

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3.

Read more Medical News

› Verified 6 days ago